Lipogems International

Lipogems International is a clinical-stage medical technology company pioneering a novel approach in regenerative medicine. Its core innovation is the Lipogems® system, a closed, minimally invasive device that harvests and processes a patient's adipose tissue to concentrate regenerative cells and factors without enzymatic manipulation or additives. The company is advancing its technology through clinical studies, including a pivotal U.S. FDA IDE trial for knee osteoarthritis, and has established a global commercial footprint for its device outside the United States. With over 140 peer-reviewed publications, Lipogems is positioning its autologous, point-of-care therapy as a safe and effective alternative or adjunct to traditional surgical interventions.

The Lipogems® system is a proprietary, closed-loop medical device for the point-of-care harvesting and mechanical processing of autologous adipose tissue. It produces a minimally manipulated, micro-fragmented adipose tissue (MFAT) graft rich in regenerative cells (MSCs, pericytes) and growth factors, without enzymatic digestion or additives.

Lipogems competes in the autologous, point-of-care regenerative medicine segment. Direct competitors include providers of bone marrow aspirate concentrate (BMAC) systems and other adipose processing devices. It also faces competition from platelet-rich plasma (PRP) therapies and, in the longer term, from allogeneic cell therapy products and disease-modifying osteoarthritis drugs (DMOADs). Its key differentiators are the specific cellular niche preserved in its MFAT product and its purely mechanical, enzyme-free processing.